Conference abstractPublished 2018
Therapeutic effects of cationic liposomes against colon carcinoma along with apoptosis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
We have produced three-component cationic liposomes (CL) composed of 87 mol% L-α-dimyristoylphosphatidylcholine, 5 mol% polyoxyethylene (21) dodecyl ether and 8 mol% O,O’-ditetradecanoyl-N-(α–trimethylammonioacetyl) diethanolamine chloride, which were effective for inhibiting the growth of colorectal cancer (CRC) cells without using drugs. Fusion and accumulation of CL including the fluorescent probe in CRC cells was observed using confocal laser microscope without affecting normal cells. This result suggests that CL selectively fused and accumulated into CRC cell membrane, which overexpressed negativelly charged sialic acid-containing glycosphingolipids. The induction of apoptosis for CRC cells treated with CL was observed using TUNEL method. Apoptotic DNA rates in CRC cells treated with CL increased and a high apoptotic DNA rate was attained. We observed activation of caspase-3, -8 and -9 and decrease in mitochondrial transmembrane potential in CRC cells treated with CL, indicating that apoptotic signal passed through caspase-3, -8 and -9 and mitochondria. Therapeutic effects of CL on xenograft and hepatic metastasis mouse model of CRC in vivo were obtained. Remarkable reduction of tumor volume was obtained in xenograft model mice of CRC intravenously treated with CL. Many apoptotic cells in tissue section of tumor in xenograft mice treated with CL were observed. Relative liver weight of hepatic metastasis mouse model decreased after the treatment with CL. Reduction of tumor in the liver of hepatic metastasis mouse model was observed. The reduction of metastatic nodules was observed in the liver using HE staining method. Induction of apoptosis in metastasis mouse model was observed using TUNEL method. CL had no side-effects in the safety tests intravenously administered in vivo. The results of this study could be potentially advantageous for future clinical application of CL therapy in patients with CRC.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalArchives in Cancer Research
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Yoko Matsumoto”
